U.S. FDA Approves Bristol Myers Squibb And 2seventy bio's Abecma For Triple-Class Exposed Relapsed Or Refractory Multiple Myeloma After Two Prior Lines Of Therapy; Abecma Tripled Progression-Free Survival Compared To Standard Regimens In The Phase 3 KarMMa-3 trial, With A 51% Reduction In Risk Of Disease Progression Or Death And A Well-Established Safety Profile
Portfolio Pulse from Benzinga Newsdesk
The U.S. FDA has approved Abecma, a CAR T cell therapy developed by Bristol Myers Squibb (BMY) and 2seventy bio (TSVT), for relapsed or refractory multiple myeloma after two prior lines of therapy. This approval, based on the Phase 3 KarMMa-3 trial, marks a significant advancement in treatment, offering a 51% reduction in disease progression or death risk and a well-established safety profile. Abecma is now available in the U.S., Japan, Switzerland, and the EU for earlier use in treating triple-class exposed relapsed and/or refractory multiple myeloma.
April 05, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's FDA approval for Abecma expands its market, potentially increasing revenue and reinforcing its position in oncology treatments.
The FDA approval of Abecma for a broader patient base in multiple myeloma treatment represents a significant milestone for Bristol Myers Squibb, likely leading to increased sales and further establishing the company as a leader in innovative oncology treatments.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
2seventy bio's collaboration with BMY on Abecma's FDA approval enhances its credibility and potential for revenue growth in the CAR T cell therapy market.
2seventy bio's role in developing Abecma and achieving FDA approval strengthens its market position and credibility in the CAR T cell therapy space, likely leading to increased investor interest and revenue opportunities.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90